Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · cited 5×
“Male mice with global glucagon receptor knockout and wild-type mice (19)”
BackgroundSelf-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345 · cited 1×
“Glucagon was immunocytochemically localized to pancreatic a-cells (3) and shown to be secreted in response to increased glucose need, as in starvation and exercise (4).”
BackgroundSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 6×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundResultSelf-citationCREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast to normal a-cells, which are restrained by the high local concentrations of intraislet insulin (22), type 1 diabetic a-cells are unregulated, which results in inappropriate hyperglucagonemia (5).”
BackgroundSelf-citationAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“More recently, the same antidiabetic efficacy has been demonstrated with recombinant leptin (11,23).”
BackgroundUnger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citation
Cited by
Items 101–200 of 326
Martin, A., Mick, G. J., Choat, H. M., Lunsford, A., Tse, H. M., McGwin, G. G., & McCormick, K. L. (2022) · Nature Communications · doi:10.1038/s41467-022-35544-3 · Cited by 53
Glucagon, a key factor in the pathophysiology of type 2 diabetes
Girard, J. R. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.004 · Cited by 50
Recent progress in the development of small-molecule glucagon receptor antagonists
Sammons, M. F., & Lee, E. C. Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.092 · Cited by 43
Inhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
Metabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
Bru-Tarí, E., Cobo‐Vuilleumier, N., Alonso‐Magdalena, P., dos Santos, R. S., Marroquí, L., Nadal, Á., Gauthier, B. R., & Quesada, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-45853-1 · Cited by 48
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“insulin secretion, is the primary cause for hyperglycemia in diabetes [3].”
Glucagon receptor inactivation leads to α-cell hyperplasia in zebrafish
Li, M., Dean, E. D., Zhao, L., Nicholson, W. E., Powers, A. C., & Chen, W. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0284 · Cited by 48
“…of Gcgr in mice results in mild hypoglycemia and decreased adiposity, and prevents diabetes induced either by streptozotocin or by a high fat diet (Gelling et al. 2003, Conarello et al. 2007, Lee et al. 2011), supporting glucagon antagonism as a potential treatment for both types of diabetes.”
Insulin and glucagon signaling in the central nervous system
Filippi, B., Abraham, M. A., Yue, J. T. Y., & Lam, T. K. T. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9258-4 · Cited by 53
“The observation that GR-null mice (Gcgr) did not become hyperglycemic despite being rendered insulin-deficient [108] further highlights the importance of glucagon in the pathogenesis of hyperglycemia in the diseased state.”
BackgroundThe Role of Glucagon in the Pathophysiology and Management of Diabetes
Kulina, G., & Rayfield, E. J. (2016) · Endocrine Practice · doi:10.4158/ep15984.ra · Cited by 51
Glucagon and Cyclic AMP: Time to Turn the Page?
L. Rodgers, R. (2012) · Current Diabetes Reviews · doi:10.2174/157339912802083540 · Cited by 42
Brain Control of Insulin and Glucagon Secretion
Osundiji, M. A., & Evans, M. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.11.006 · Cited by 42
“action protects against ketoacidosis, suggesting that, in the presence of insulinopenia, a relative hyperglucagonemia may contribute to the metabolic disturbances seen in type 1 diabetes.(6) In addition, loss of glucagon responses to hypoglycemia is”
BackgroundPancreatic α-Cell Hyperplasia: Facts and Myths
Yu, R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2952 · Cited by 39
Yip, L., Taylor-Edwards, C., Whiting, C. C., & Fathman, C. G. (2013) · Diabetes · doi:10.2337/db13-0614 · Cited by 43
“Streptozotocin-induced b-cell destruction does not lead to hyperglycemia in glucagon-receptor KO mice (48) or in rats treated with a glucagon receptor antagonist (50).”
BackgroundFasting Hormones Synergistically Induce Amino Acid Catabolism Genes to Promote Gluconeogenesis
Korenfeld, N., Finkel, M., Buchshtab, N., Bar‐Shimon, M., Charni‐Natan, M., & Goldstein, I. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.04.017 · Cited by 46
Leptin, 20years of searching for glucose homeostasis
Fernández-Formoso, G., Perez‐Sieira, S., González-Touceda, D., Diéguez, C., & Tovar, S. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.008 · Cited by 41
“Moreover, glucagon receptor null mice are resistant to developing the diabetes induced by STZ treatment or Alloxan [89], suggesting that glucagon signaling is required for diabetic hyperglycemia.”
BackgroundSteenberg, V. R., Jensen, S. M., Pedersen, J., Madsen, A. N., Windeløv, J. A., Holst, B., Quistorff, B., Poulsen, S. S., & Holst, J. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3794-2 · Cited by 37
A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis
Ramakrishnan, S. K., & Shah, Y. M. (2017) · Nutrition and Healthy Aging · doi:10.3233/nha-170022 · Cited by 39
“[68] Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH.”
BackgroundKostic, A., King, T. A., Yang, F., Chan, K., Yancopoulos, G. D., Gromada, J., & Harp, J. B. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13075 · Cited by 36
Glucagon regulates hepatic mitochondrial function and biogenesis through FOXO1
Yang, W., Yan, H., Pan, Q., Shen, Z., Zhou, F., Wu, C., Sun, Y., & Guo, S. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0081 · Cited by 37
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Mandaliya, D. K., & Seshadri, S. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.013 · Cited by 43
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia
Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.10.029 · Cited by 35
“Additionally, recent studies have shown that hyperglycaemia and ketosis in rodent models of type 1 diabetes and type 2 diabetes, respectively, can be abrogated by knocking out the glucagon receptor [8,9]; stressing the importance of glucagon in the pathophysiology of diabetes.”
BackgroundLang, S., Yang, J., Yang, K., Gu, L., Cui, X., Wei, T., Liu, J., Le, Y., Wang, H., Wei, R., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001025 · Cited by 38
Ben-Zvi, D., Barrandon, O., Hadley, S., Blum, B., Peterson, Q. P., & Melton, D. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513872112 · Cited by 34
“Glucagon has received increasing attention after glucagon receptor knockout mice (gcgr) were shown to be protected from development of diabetes in type 1 and type 2 diabetes models (8, 9).”
BackgroundAptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases
Hu, J., Ye, M., & Zhou, Z. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1485-1 · Cited by 36
Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade
Mani, B. K., Uchida, A., Lee, Y., Osborne-Lawrence, S. L., Charron, M. J., Unger, R. H., Berglund, E. D., & Zigman, J. M. (2017) · Diabetes · doi:10.2337/db16-1303 · Cited by 34
“Contribution by ghrelin to the plasma elevation of glucagon and GLP-1 and/or to a-cell hyperplasia in Gcgr mice or in humans with loss-of-function GcgR mutations (4,24,33) are interesting possibilities that should be explored, especially in light of the proposed important roles diabetes.”
BackgroundMethodInfluentialSelf-citationNeumann, U. H., Ho, J. S. S., Chen, S., Tam, Y. Y. C., Cullis, P. R., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.012 · Cited by 38
“Diabetes induced by 1 or 2 high dose STZ injections results from severe insulin deficiency and is commonly used in studies testing glucagon suppression therapy [6,8] or leptin therapy [13,20,32,33].”
BackgroundMethodMeek, T. H., Dorfman, M. D., Matsen, M. E., Fischer, J. D., Cubelo, A., Kumar, M. R., Taborsky, G. J., & Morton, G. J. (2015) · Diabetes · doi:10.2337/db14-1562 · Cited by 34
“Indeed, data from GcgR-deficient mice suggest that glucagon signaling is required for diabetes pathogenesis (4,5), but efforts to generalize such findings to genetically intact animals should be made with caution, since both basal and stimulated glucagon action are abolished in this model.”
BackgroundNiwano, F., Hiromine, Y., Noso, S., Babaya, N., Ito, H., Yasutake, S., Matsumoto, I., Takeyama, Y., Kawabata, Y., & Ikegami, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12799 · Cited by 33
Pancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis
Wendt, A., & Eliasson, L. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102199 · Cited by 37
Aptamer Oligonucleotides: Novel Potential Therapeutic Agents in Autoimmune Disease
Li, W., & Lan, X. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0529 · Cited by 33
“Thus, glucagon antagonists may be employed to reduce the hyperglycemic response to glucagon in DM patients [14,15].”
Chowdhury, M. K. H., Turner, N. A., Bentley, N. L., Das, A., Wu, L. E., Richani, D., Bustamante, S., Gilchrist, R. B., Morris, M. J., Shepherd, P. R., et al. (2017) · Scientific Reports · doi:10.1038/srep40159 · Cited by 37
“But under pathophysiological conditions such as T2D, hyperglucagonemia is strongly linked to maintaining high blood glucose levels 6–8 , 10 .”
Neumann, U. H., Ho, J. S. S., Mojibian, M., Covey, S. D., Charron, M. J., & Kieffer, T. J. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.014 · Cited by 29
“Furthermore, it has been shown that Gcgr gene deletion normalizes ketones [3].”
BackgroundInfluentialSelf-citationCNS Regulation of Glucose Homeostasis: Role of the Leptin-Melanocortin System
da Silva, A. A., do Carmo, J. M., & Hall, J. E. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01311-1 · Cited by 32
Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
Bozadjieva-Kramer, N., Lubaczeuski, C., Blandino-Rosano, M., Barker, G. P., Gittes, G. K., Caicedo, A., & Bernal‐Mizrachi, E. (2020) · Diabetes · doi:10.2337/db20-0440 · Cited by 35
Lotfy, M. A., Kalász, H., Szalai, G., Singh, J., & Adeghate, E. A. (2014) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501408010028 · Cited by 33
“Other studies reported that glucagon immunoneutralization leads to a marked decrease in glucagon levels and improve glucose tolerance in experimental animals [18, 19].”
BackgroundInfluentialCell Autonomous Dysfunction and Insulin Resistance in Pancreatic α Cells
Honzawa, N., Fujimoto, K., & Kitamura, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153699 · Cited by 33
“When STZ was administered to glucagon receptor-deficient mice, the blood glucose levels remain normal even when insulin secretion is suppressed [11].”
Acetyl-CoA-carboxylase 1 (ACC1) plays a critical role in glucagon secretion
Veprik, A., Denwood, G., Liu, D., Bakar, R. B., Morfin, V., McHugh, K., Tebeka, N. N., Vetterli, L., Yonova‐Doing, E., Gribble, F. M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03170-w · Cited by 34
Nakashima, K., Kaneto, H., Shimoda, M., Kimura, T., & Kaku, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21751-w · Cited by 32
Cullen, K. S., Al‐Oanzi, Z. H., O'Harte, F. P. M., Agius, L., & Arden, C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.02.006 · Cited by 29
“Compelling evidence for an over-riding role for glucagon excess in the pathogenesis of diabetes [3,14] and development of non-invasive methods for estimating glucokinase activity in man based on the assumption that glucokinase activity responds to glucose but not to hormones [15,16], calls for a critical re-evaluation…”
BackgroundFedorova, N. V., Ksenofontov, A. L., Serebryakova, M. V., Stadnichuk, V. I., Gaponova, T. V., Baratova, L. A., Sud’ina, G. F., & Galkina, S. I. (2018) · Mediators of Inflammation · doi:10.1155/2018/1574928 · Cited by 28
A neural basis for brain leptin action on reducing type 1 diabetic hyperglycemia
Fan, S., Xu, Y., Lu, Y., Jiang, Z., Li, H., Morrill, J., Cai, J., Wu, Q., Xu, Y., Xue, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22940-4 · Cited by 28
“mice presented in panels f–i, comparisons were shown in glucose levels between fed and fasting, and between saline and leptin treatment conditions (j, oneway ANOVA, n= 5/each, F(2, 8)= 116.”
MethodIntra-islet glucagon secretion and action in the regulation of glucose homeostasis
Wang, Q., Liang, X., & Wang, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2012.00485 · Cited by 29
“Furthermore, pancreas perfusion studies using specific GCGR antagonists suggested that the intraislet glucagon-induced trophic effects on the β-cells are mainly through GCGR rather than GLP-1 receptors on islet β-cells (Kawai et al., 1995), although the gut-derived insulinotropic hormone is…”
Intercellular Communication in the Islet of Langerhans in Health and Disease
Ng, X. W., Chung, Y. H., & Piston, D. W. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200026 · Cited by 43
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone, E. R., Bloom, S. R., & Tan, T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0365 · Cited by 30
“Further investigation, however, demonstrated that resistance to hyperglycaemia persists in GCGR −/− mice even after a double dose of STZ ensures dramatic reduction in circulating insulin (Lee et al. 2011).”
BackgroundMadi, A., Bransburg‐Zabary, S., Maayan‐Metzger, A., Dar, G., Ben‐Jacob, E., & Cohen, I. R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402771 · Cited by 26
Onodera, T., Zadeh, E. H. G., Xu, P. H., Gordillo, R., Guo, Z., Joffin, N., Yu, B., Scherer, P. E., & Li, W. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100095 · Cited by 27
Early milestones in glucagon research
Lefèbvre, P. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01437.x · Cited by 26
Sloan, J. H., Siegel, R. W., Ivanova-Cox, Y. T., Watson, D. E., Deeg, M. A., & Konrad, R. J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.07.111 · Cited by 29
Sun, G., Xavier, G. D. S., Gorman, T., Priest, C., Solomou, A., Hodson, D. J., Foretz, M., Viollet, B., Herrera, P. L., Parker, H., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.006 · Cited by 24
“The concept that modulation of glucagon levels may represent a useful therapeutic approach to some forms of diabetes has existed for many years [44] and was further supported recently by two separate studies in which mice null for glucagon receptors were shown to be resistant to beta cell destruction by streptozotocin…”
ResultGlucagon therapeutics: Dawn of a new era for diabetes care
Davidson, J. A., Holland, W. L., Roth, M. G., Wang, M.-Y., Lee, Y., Yu, X., McCorkle, S. K., Scherer, P. E., & Unger, R. H. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2773 · Cited by 26
“Thus, in rodents with congenital absence of glucagon receptor, it is possible to destroy all their beta cells without even causing abnormal glucose tolerance [15].”
BackgroundSelf-citationIida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3935-2 · Cited by 27
“It has been shown recently that administration of STZ to Gcgr mice disrupted 90% of the beta cells and abolished glucose-induced insulin secretion yet failed to cause hyperglycaemia [10].”
Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways
Yagi, T., Kubota, E., Koyama, H., Tanaka, T., Kataoka, H., Imaeda, K., & Joh, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24367 · Cited by 29
“Glucagon works mainly to increase blood glucose levels through activating glycogenolytic and gluconeogenic pathways, and recent evidence suggests that glucagon is a key contributing factor to the development and progression of diabetes [19, 30].”
BackgroundIncretin-based therapies for patients with type 1 diabetes: a meta-analysis
Liu, L., Shao, Z., Xia, Y., Qin, J., Xiao, Y., Zhou, Z., & Mei, Z. (2019) · Endocrine Connections · doi:10.1530/ec-18-0546 · Cited by 26
Asadi, F., & Dhanvantari, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.726368 · Cited by 28
“Support for the latter hypothesis seemed to be provided by studies showing that glucagon receptor knockout mice are resistant to the effects of beta cell deficiency induced by streptozotocin treatment (5, 6), providing evidence that blocking glucagon action can provide glycemic control even in the relative absence of…”
BackgroundNeutrophils as a source of branched-chain, aromatic and positively charged free amino acids
Galkina, S. I., Fedorova, N. V., Ksenofontov, A. L., Stadnichuk, V. I., Baratova, L. A., & Sud’ina, G. F. (2018) · Cell Adhesion & Migration · doi:10.1080/19336918.2018.1540903 · Cited by 24
Insulin Knockout Mice Have Extended Survival but Volatile Blood Glucose Levels on Leptin Therapy
Neumann, U., Denroche, H. C., Mojibian, M., Covey, S. D., & Kieffer, T. J. (2015) · Endocrinology · doi:10.1210/en.2015-1890 · Cited by 26
Leptin therapy in type 2 diabetes
Cummings, B. P. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12048 · Cited by 23
Petersen, N., Wu, B., & Han, W. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2888-2_32 · Cited by 26
Grover, S., Dhanjal, J. K., Goyal, S., Grover, A., & Sundar, D. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s16-s13 · Cited by 23
“mice prevents the deadly metabolic and clinical phenotype of type 1 diabetes [7].”
BackgroundRivero‐Gutiérrez, B., Haller, A. M., Holland, J., Yates, E., Khrisna, R., Habegger, K. M., DiMarchi, R. D., D’Alessio, D. A., & Pérez–Tilve, D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.012 · Cited by 24
“Indeed, congenital mouse models of loss of Gcgr expression (Gcgr / mice) exhibit reduced baseline blood glucose, improved glucose tolerance, and even more strikingly, the maintenance of normoglycemia and increased survival following the destruction of beta-cells with STZ [3,5].”
InfluentialHigh-fat diet impacts more changes in beta-cell compared to alpha-cell transcriptome
Dusaulcy, R., Handgraaf, S., Visentin, F., Howald, C., Dermitzakis, E. T., Philippé, J., & Gosmain, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213299 · Cited by 29
Kobayashi, M., Satoh, H., Matsuo, T., Kusunoki, Y., Tokushima, M., Watada, H., Namba, M., & Kitamura, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0079 · Cited by 24
Alpha cell function in type 1 diabetes
Hughes, D. S., & Narendran, P. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.014 · Cited by 30
“Novel dual GLP-1/glucagon receptor and GLP-1/GIP receptor targeted peptides have been shown to treat hyperglycaemia in mice.62-64 In animal studies, circulating glucagon is decreased following therapy with ghrelin antagonists, and with leptin ago- nists.65,66 These therefore have therapeutic potential, and the leptin…”
BackgroundInfluentialMeek, T. H., Matsen, M. E., Damian, V. M., Cubelo, A., Chua, S. C., & Morton, G. J. (2014) · Endocrinology · doi:10.1210/en.2014-1169 · Cited by 24
Pujar, M. S., Vastrad, B. M., Kavatagimath, S., Vastrad, C. M., & Kotrashetti, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13291-1 · Cited by 25
Cui, X., Feng, J. B., Wei, T., Gu, L., Wang, D., Lang, S., Yang, K., Yang, J., Yan, H., Wei, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104567 · Cited by 23
Taurine rescues pancreatic β‐cell stress by stimulating α‐cell transdifferentiation
Sarnobat, D., Moffett, R. C., Ma, J., Flatt, P. R., McClenaghan, N. H., & Tarasov, A. I. (2023) · BioFactors · doi:10.1002/biof.1938 · Cited by 25
“The latter are believed to upregulate glucagon release in models utilizing higher doses of STZ,(62,63) or allowing for longer progression of the phenotype.(63,64) Notably, taurine administration was able to reverse the tendency for the β-cell loss (Figure 2B), evidently by decreasing apoptosis (Figure 3A) and increasi…”
BackgroundAbarkan, M., Gaitan, J., Lebreton, F., Perrier, R., Jaffredo, M., Mulle, C., Magnan, C., Raoux, M., & Lang, J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.011 · Cited by 26
Xu, Y., Chang, J. T., Myers, M. G., Xu, Y., & Tong, Q. (2016) · Diabetes · doi:10.2337/db15-1160 · Cited by 22
“Indeed, glucagon receptor deficiency abrogates the hyperglycemia-producing effects by lesion of pancreatic b-cells (6).”
BackgroundWang, L., Luk, C. T., Cai, E. P., Schroer, S. A., Allister, E. M., Shi, S. Y., Wheeler, M. B., Gaisano, H. Y., & Woo, M. (2014) · Diabetes · doi:10.2337/db13-1715 · Cited by 23
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
“quate insulin therapy), and absent or severely impaired glucagon response during hypoglycemia.[8] Liraglutide is a once-daily (QD) long-acting GLP-1 receptor agonist (GLP-1RA) approved for the treatment of type 2 diabetes.”
BackgroundPedersen, C., Porsgaard, T., Thomsen, M., ROSENKILDE, M. M., & Roed, N. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194468 · Cited by 21
In situ microwave fixation provides an instantaneous snapshot of the brain metabolome
Juras, J. A., Webb, M. B., Young, L. E. A., Markussen, K. H., Hawkinson, T. R., Buoncristiani, M. D., Bolton, K. E., Coburn, P. T., Williams, M. I., Sun, L. P. Y., et al. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100455 · Cited by 28
Soares, A. F., Carvalho, R. A., Veiga, F., Alves, M. G., Martins, F. O., Viegas, I., González, J. D., Metón, I., Baanante, I. V., & Jones, J. G. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00161.2012 · Cited by 22
“For example, the deletion of the glucagon receptor in mice is sufficient to prevent the development of type 1 diabetes symptoms after STZ (27) and aloxan treatments (63).”
BackgroundDusaulcy, R., Handgraaf, S., Heddad-Masson, M., Visentin, F., Vesin, C., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2015) · Endocrinology · doi:10.1210/en.2015-1725 · Cited by 25
“Maximal effect of STZ is observed about 1 week after injection (9).”
BackgroundShang, W., Si, X., Zhou, Z., Strappe, P., & BLANCHARD, C. L. (2018) · Food & Function · doi:10.1039/c8fo00331a · Cited by 20
Grøndahl, M. F. G., Keating, D. J., Vilsbøll, T., & Knop, F. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0967-z · Cited by 23
Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Usui, R., Yabe, D., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13005 · Cited by 20
Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1
Perry, R. J. (2022) · Diabetes · doi:10.2337/dbi22-0003 · Cited by 20
The human α cell in health and disease
Pettway, Y. D., Saunders, D. C., & Briššová, M. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0298 · Cited by 24
Roberts, D. J., Vertongen, P., & Waelbroeck, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.06.009 · Cited by 19
Postprandial Suppression of Glucagon Secretion: A Puzzlement
Geary, N. (2017) · Diabetes · doi:10.2337/dbi16-0075 · Cited by 19
“Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB.”
BackgroundTuazon, M. A., McConnell, T. R., Wilson, G. J., Anthony, T. G., & Henderson, G. C. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00440.2014 · Cited by 19
Murai, N., Ohtaki, H., Watanabe, J., Xu, Z., Sasaki, S., Yagura, K., Shioda, S., Nagasaka, S., Honda, K., & Izumizaki, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186637 · Cited by 22
Zhang, Y., Thai, K., Jin, T., Woo, M., & Gilbert, R. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-32351-z · Cited by 20
Absence of leptin triggers type 1 diabetes
Mittendorfer, B., & Klein, S. (2014) · Nature Medicine · doi:10.1038/nm.3629 · Cited by 20
Glucagon Responses of Isolated a Cells to Glucose, Insulin, Somatostatin, and Leptin
Chen, L., Philippé, J., & Unger, R. H. (2011) · Endocrine Practice · doi:10.4158/ep11101.or · Cited by 19
Self-citationFarhy, L. S., & McCall, A. L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01455.x · Cited by 19
“Similarly, a knockout of glucagon receptors in an animal model also seems to stabilize insulindeficient diabetes [23].”
BackgroundViloria, K., Nasteska, D., Ast, J., Hasib, A., Cuozzo, F., Heising, S., Briant, L. J. B., Hewison, M., & Hodson, D. J. (2022) · Diabetes · doi:10.2337/db22-0326 · Cited by 16
“against diabetes (9; 10), and that immunoneutralization of glucagon restores glucose 50 homeostasis in STZ-treated rats (11) or obese mice (12).”
BackgroundSugiyama, C., Yamamoto, M., Kotani, T., Kikkawa, F., Murata, Y., & Hayashi, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043745 · Cited by 17
“It is also noteworthy that amino acid metabolism is altered in both Gcg and Gcgr mice and that both show hyperaminoacidemia [31,32], as hyperaminoacidemia is observed in poorly controlled GDM and is associated with poor outcome [33].”
BackgroundIrwin, N., Franklin, Z. J., & O'Harte, F. P. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.041 · Cited by 16
Pérez, Á., Rojas, P., Carrasco, F., Basfi-fer, K., Pérez‐Bravo, F., Codoceo, J., Inostroza, J., & Ruz, M. (2018) · Biological Trace Element Research · doi:10.1007/s12011-018-1249-6 · Cited by 17
Lou, P., Petersen, N., Wang, Y., Radda, G. K., & Han, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026671 · Cited by 19
“Various pharmacological and genetic approaches have been used to evaluate the glycemic advantage of reduced glucagon production or signalling: (i) blocking glucagon signalling by targeted glucagon receptor gene deletion [9,10,11]; (ii) removal of endogenous glucagon using high affinity glucagon-neutralizing antibodies…”
Chen, Y., Wang, B., Ou, X., Wu, Y., He, Y., Lin, X., & Lin, X. (2022) · Journal of Virology · doi:10.1128/jvi.01020-22 · Cited by 15
“Deletion of GCGR maintained normal blood glucose and improved glucose tolerance in diabetes (13, 14).”
BackgroundFactors Affecting Insulin-Regulated Hepatic Gene Expression
Guan, H.-P., & Chen, G. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00006-5 · Cited by 18
Ubiquitin-dependent proteolysis of CXCL7 leads to posterior longitudinal ligament ossification
Tsuru, M., Ono, A., Umeyama, H., Takeuchi, M., & Nagata, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196204 · Cited by 16
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Guo, K., Tian, Q., Yang, L., & Zhou, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s343514 · Cited by 20
Franklin, Z. J., O'Harte, F. P. M., & Irwin, N. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0224 · Cited by 15
Jones, H. B., Reens, J., Brocklehurst, S. R., Betts, C. J., Bickerton, S., Bigley, A. L., Jenkins, R. P., Whalley, N., Morgan, D., & Smith, D. M. (2014) · International Journal of Experimental Pathology · doi:10.1111/iep.12066 · Cited by 15
“Substantial data obtained from studies of glucagon receptor knockout mice (Parker et al. 2002; Gelling et al. 2003; Connarello et al. 2007; Lee et al. 2011), glucagon gene knockout mice (Hayashi et al.”
Background
Metadata
- Authors
- Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Albert Einstein College of Medicine (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028337
- OpenAlex
- W1986861420
- Cited by
- 327
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.